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Background: Drug dosing errors are common in renal-impaired patients. Appropriate dosing adjustment and drug
selection is important to ensure patients’ safety and to avoid adverse drug effects and poor outcomes. There are
few studies on this issue in community pharmacies. The aims of this study were, firstly, to determine the prevalence
of dosing inadequacy as a consequence of renal impairment in patients over 65 taking 3 or more drug products
who were being attended in community pharmacies and, secondly, to evaluate the effectiveness of the community
pharmacist’s intervention in improving dosing inadequacy in these patients when compared with usual care.
Methods: The study was carried out in 40 Spanish community pharmacies. The study had two phases: the first,
with an observational, multicentre, cross sectional design, served to determine the dosing inadequacy, the
drug-related problems per patient and to obtain the control group. The second phase, with a controlled study with
historical control group, was the intervention phase. When dosing adjustments were needed, the pharmacists
made recommendations to the physicians. A comparison was made between the control and the intervention
group regarding the prevalence of drug dosing inadequacy and the mean number of drug-related problems per
patient.
Results: The mean of the prevalence of drug dosing inadequacy was 17.5% [95% CI 14.6-21.5] in phase 1 and
15.5% [95% CI 14.5-16.6] in phase 2. The mean number of drug-related problems per patient was 0.7 [95% CI 0.5-0.8] in
phase 1 and 0.50 [95% CI 0.4-0.6] in phase 2. The difference in the prevalence of dosing inadequacy between the
control and intervention group before the pharmacists’ intervention was 0.73% [95% CI (−6.0) - 7.5] and after the
pharmacists’ intervention it was 13.5% [95% CI 8.0 - 19.5] (p < 0.001) while the difference in the mean of drug-related
problems per patient before the pharmacists’ intervention was 0.05 [95% CI( -0.2) - 0.3] and following the intervention
it was 0.5 [95% CI 0.3 - 0.7] (p < 0.001).
Conclusion: A drug dosing adjustment service for elderly patients with renal impairment in community pharmacies
can increase the proportion of adequate drug dosing, and improve the drug-related problems per patient.
Collaborative practice with physicians can improve these results.
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Chronic Kidney Disease (CKD) is an important health
problem with high incidence and prevalence and a close
association with cardiovascular diseases and diabetes
[1,2]. In the United States, the estimated prevalence for
chronic renal impairment in adults is 13% [3] and in the
Spanish population it is 6.8% (ages ≥ 20) and 21.4% (ages >
64) [4]. In patients with hypertension and diabetes, the
prevalence of CKD can reach up to 35-40% [5] and, in the
elderly, it rises exponentially [6].
Inadequate dosing adjustment in renally excreted drugs is
one of the main causes of iatrogenesis [7]. Unsuitable dos-
ing or frequency of administration is considered be respon-
sible for about 70-75% errors in these drugs [8].
A drug-related problem (DRP) is defined as an event
or circumstance involving drug therapy that actually or
potentially interferes with desired health outcomes [9].
About one third of hospital admissions as a conse-
quence of a DRP have been registered in patients over
60 years [10] and half of these are due to adverse drug
events (ADEs) [11].
DRPs are the fourth cause of elderly mortality in the
USA and have a negative impact on mortality, morbidity,
functionality, and resource availability and use [11].PHASE 1
Determination of prevalence of dosing 
inadequacy and DRPs rate
22 community pharmacies
N = 566 patients screened
1922 drugs with renal restrictions
N = 263 patients with renal impairment
(FGR or ClCr<60 mL/min/1.73m2)
1049 drugs with renal restrictions
176 patients were randomly selected to 
be used a comparator group for Phase 2 
700 drugs with renal restrictions
CONTROL GROUP
EXCLUDED N = 303
N = 300 without renal 
impairment 
N = 3 not taking drugs 
with renal restrictions
Figure 1 General schema of study.Pharmacist care tries to ensure the effective and safe
use of drugs for patients to enhance their quality of life.
Safety is a key element in avoiding side effects through
early detection of DRPs.
Studies conducted in hospital settings and residential
homes in which the pharmacist tried to prevent and
treat DRPs in elderly, renally-impaired patients produced
positive results in terms of patients’ health [12-15]. Re-
cently, other studies [16,17] showed a reduction in medi-
cation errors and in inappropriately high doses of renally
excreted medications in patients with CKD in ambula-
tory or primary care settings. However, according to a
recent systematic review [18], no studies have been
conducted in community pharmacies.
The aims of this study were to determine the
prevalence of dosing inadequacy as a consequence of
renal impairment in patients over 65 that were tak-
ing 3 or more drug products and who were being
attended in community pharmacies, and to evaluate
the effectiveness of the community pharmacist inter-
vention in addressing the problem of dosing inad-
equacy as a consequence of renal impairment in
patients over 65 years that were taking 3 or more
drugs when compared with usual care.PHASE 2
Determination of effectiveness of 
community pharmacist intervention
18 community pharmacies
N = 440 patients screened
1392 drugs with renal restrictions 
N = 178 with renal impairment
(FGR or ClCr<60 mL/min/1.73m2
614 drugs with renal restrictions
INTERVENTION GROUP
EXCLUDED N = 262
N = 258 without renal 
impairment 
N = 4 not taking drugs 
with renal restrictions
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Design
This study consists of two phases (Figure 1):
Phase 1: To determine the prevalence of dosing
inadequacy, an observational, multicentre,
cross-sectional study was carried out.
Phase 2: To evaluate the effectiveness of the
community pharmacist intervention, a non-
randomised controlled study with historical control
group was carried out. The Ethics Committee at
Germans Trias i Pujol Hospital revised and approved
the study (EO-12-038).
Setting and participants
The study was carried out by 40 volunteer pharmacists
in 40 community pharmacies, accredited by the Univer-
sity of Barcelona for training senior pharmacy students,
from various areas of Barcelona (Spain): Barcelonès nord,
Maresme, Vallès occidental, Vallès oriental, Berguedà and
Osona. The participant pharmacists received two sessions
(8 hours) of training prior to the study in which they were
trained to detect a patient with renal impairment and
make a dosage adjustment if needed.
Patients over 65 years old that presented to one of the
participant community pharmacies with 3 or more pre-
scriptions were invited to participate in the trial by the
pharmacists (Phase 1: Oct 2010-Jan 2011; Phase 2: Feb
2011-May 2011). The inclusion criteria were: people over
65 years old; taking 3 or more drug products; having a
Body Mass Index (BMI) between 19 and 35 Kg/m2; not
being vegetarian or on a high protein diet; not having had
a limb amputated, paralysis or muscular diseases; not tak-
ing creatinine-affecting drugs. Written informed consent
was obtained for all participants.
Participants were screened by pharmacists (a minimum
of 25 participants screened per pharmacist) for renal im-
pairment by measuring the glomerular filtration rate (GFR)
and creatinine clearance (CrCl). Serum creatinine values
were used to calculate the CrCl (Cockcroft-Gault method)
and the glomerular filtration rate (Modification of Diet in
Renal Disease MDRD-4 method) with the help of an online
renal calculator [19]. Patients with GFR levels lower than
60 ml/min/1.73 m2 and/or a CrCl lower than 60 ml/min
were considered as having a renal impairment and were in-
cluded in the study (Figure 1).
Variables
Data on variables were collected by the pharmacist in an
interview with the patient at the community pharmacy.
Sociodemographic variables: age and gender; anthropo-
metric variables: Height (m), measured through calibrated
height scales; weight (Kg): measured through calibrated
weight scales; Body Mass Index (BMI): in kg/m2; Bodysurface area (m2) calculated through Mosteller’s method
[19]. Clinical Variables: Blood Pressure (BP) (mmHg),
measured through calibrated and validated instruments;
Serum creatinine (SCr) in mg/dL through Reflotron® or
blood test conducted in the previous 3 months at the Pri-
mary Care Health Centre; comorbidity (hypertension, dia-
betes, dyslipidemia, hyper/hypo thyroidism, cardiovascular
disease (CVD) reported by the patient). Pharmacological
treatment: anatomical and therapeutic and chemical group
(ATC), active ingredient, doses, dosage, and dosing interval.
Intervention
Certain drug databases, such as CIMA [20] (Medicines
Online Information Centre) the Spanish official drugs In-
formation, Martindale [21] and American Hospital Formu-
lary Drug System Information [22] (AHFS), were consulted
to study the dosing inadequacy of the active ingredients
contained in the drug products that the patients were
taking. When an active ingredient requiring dose adjust-
ment (Cause of DRP Code C3.2, C3.4 of Classification of
Pharmaceutical Care Network Europe Foundation PCNE)
[9] was detected or when it was contra-indicated (Code
C1.1 of PCNE) [9], we considered the patient as having a
potential DRP (PCNE Code P2.1, P2.3) [9].
The prevalence of dosing inadequacy (DI) was calculated
through the mathematical expression [12]: DI = (Nº inad-
equately adjusted and/ or contra-indicated drugs / Nº total
adjustable drugs)*100
Pharmacists used a questionnaire prepared by the re-
search team to write a brief report to the general practi-
tioner (GP) detailing the problems that had been detected
and suggesting changes in pharmacological treatment
(change drug, decrease quantity of dosage, lengthen time
interval between doses). In this written report there was a
space that allowed the GPs to provide the pharmacists with
a written answer. These written reports were delivered to
the GPs by the pharmacists (face-to-face or using the GP’s
mailboxes). After 7–14 days the pharmacists went to the
Primary Care Health Centre (PCHC) to collect any replies
from the GPs. The reports included the pharmacists’ tele-
phone numbers to allow the GPs to contact them.
Sample size calculation
In Phase 1 the objective was to determine the prevalence
of dosing inadequacy in the elderly polymedicated popu-
lation with renal impairment. Assuming that the preva-
lence of dosing inadequacy in the elderly is 20%, as has
been previously reported [12], and to obtain a precision
of 3% with a 95% confidence interval, the sample size re-
quired was 683 drug products with restrictions in case
of renal impairment.
In the second phase, the aim was to evaluate the ef-
fectiveness of the community pharmacist intervention
in addressing the problem of dosing inadequacy when
Table 1 Patient demographic and clinical characteristics
at baseline according to gender (Phase 1)
Mean ± SD Women(173) Men(90) Overall(263)
Age (years) 83.1 ± 7.2 82.6 ± 6.9 82.9 ± 7.1
Weight (kg) 62.9 ± 11.6 73.9 ± 10.1 69.8 ± 12.2
Height (m) 1.5 ± 0.1 1.6 ± 0.1 1.6 ± 0.1
BMI (Kg/m2) 26.4 ± 4.1 27.0 ± 3.2 26.6 ± 3.9
SBP (mm Hg) 130.6 ± 17.5 130.9 ± 17.7 130.7 ± 17.5
DBP (mm Hg) 70.8 ± 11.1 71.7 ± 11.3 71.1 ± 11.2
Creatinine (mg/dl) 1.1 ± 0.9 1.30 ± 0.4 1.2 ± 0.8
Body surface (m2) 1.6 ± 0.2 1.8 ± 0.1 1.7 ± 0.2
GFR (ml/min/1.73 m2) 61.0 ± 16.9 59.2 ± 16.1 60.4 ± 16.7
CrCl (ml/min) 43.0 ± 11.7 47.5 ± 12.9 45.2 ± 12.2
CrCl-BS (ml/min/1.73 m2) 46.7 ± 11.6 44.5 ± 10.9 45.0 ± 11.4
Total number drugs patient 7.3 ± 3.0 7.2 ± 2.9 7.3 ± 2.9
Drugs with restrictions
per patient
4.0 ± 1.9 4.0 ± 2.9 4.0 ± 2.0
Number of DRP per patient 0.7 ± 1.1 0.6 ± 1.1 0.7 ± 1.1
Prevalence of DI (%) 18.3 ± 28.9 15.8 ± 28.4 17.5 ± 28.2
Population with DRP %(n) 35.6(32) 38.2(66) 37.3(98)
Comorbidity %(n)
Hypertension 71.7%(124) 67.8%(61) 70.3%(185)
T2DM 19.7%(34) 24.4%(22) 21.3%(56)
Dyslipidemia 37.0%(64) 36.7%(33) 36.9%(97)
Hyper/Hypo Thy 8.1(14) 1.1%(1) 5.7%(15)
CVD 26.6(46) 31.1%(28) 28.1%(74)
Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure, DBP Diastolic
Blood Pressure, T2DM Type 2 Diabetes Mellitus, CVD Cardiovascular Disease,
THY Thyroidsm, GFR Rate of Glomerular filtration, CrCl Creatinine Clearance,
CrCl-BS Creatinine Clearance adjusted to body surface, RI renal impairment,
DRP Drug-related problem, DI Dosing inadequacy, Drugs with restrictions
(dose adjustment needed in case of renal impairment (RI)) per patient [20-22],
SD Standard deviation.
Via-Sosa et al. BMC Family Practice 2013, 14:96 Page 4 of 9
http://www.biomedcentral.com/1471-2296/14/96compared with usual care. Taking into account expected
dosing inadequacy values of 20% in the control group
and 10% in the intervention group and to detect differ-
ences between groups in the levels of dosing inadequacy
with a power of 95% and a 95% confidence interval, a
minimum of 328 drug products with restrictions in case
of renal impairment per group was required.
The number of drug products needed to assess the prev-
alence of requirements for dosing adjustments was higher
than the number of drugs needed to evaluate the effec-
tiveness of the pharmacist intervention. Consequently, 176
patients from the 263 that had been included in Phase 1
formed a randomly chosen subsample to be used as histo-
rical control group in Phase 2 (Figure 1).
Statistical analysis
Data analysis was performed using the Statistical Pack-
age for the Social Sciences version 19 (SPSS). Quantita-
tive variables were expressed as means. Other variables
were expressed as relative and absolute frequencies. The
comparison between variables was conducted using the
Chi-Squared test and Student’s t-test for qualitative and
quantitative variables, respectively. ANOVA was also used
to compare qualitative variables for multiple layer quanti-
tative analyses. P values less than 0.05 were considered sta-
tistically significant. Population parameter estimates were
carried out at a Confidence Interval (CI) of 95%.
Results
Phase 1: cross sectional descriptive study
In the first phase, 22 community pharmacies and 566 pa-
tients participated. Glomerular filtration analysis showed
266 patients with some degree of renal impairment
(CrCl < 60 ml/min and/or GFR < 60 ml/min/1.73 m2) in
the screening performed by pharmacists. Three patients
were excluded because they were not taking any drug with
restrictions in the case of renal impairment (Figure 1).
Table 1 shows the patients’ baseline characteristics by
gender.
The 263 patients included were taking a total of 1,922
drug products of which 1,049 [54.6% 95% CI 52.3-56.7]
may have dosing restrictions or be contraindicated de-
pending on patient’s renal functioning. The mean of the
prevalence of dosing inadequacy in this group was 17.5%
[95% CI 14.6 - 21.4] and the mean of DRPs per patient
was 0.7 [95% CI 0.5-0.8] (Table 1).
The active ingredients contained in these 1,049 drug
products that may have needed dose adjustments or were
contra-indicated in case of renal impairment were distrib-
uted among eleven anatomical groups (Figure 2). The ana-
tomical group that presented most drugs was group C
which corresponds to the Cardiovascular System. Four out
of every ten drugs used by patients belonged to this group.
Most of the drugs work on the renin-angiotensin system(C09) (ACE inhibitors, Angiotensin II antagonists) and
were followed by diuretics (C03) (thiazides) and HMG-
CoA Reductase Inhibitors (statins) C10. The N group refers
to the Nervous System and also presented a high prescrip-
tion percentage; three of every ten drugs belonged to this
group. The analgesics (N02), psycholeptics (N05) and psy-
choanaleptics (N06) subgroups were the most frequent. In
the A group (Alimentary tract and metabolism) it is notable
that the most prescribed drugs were those used to treat dia-
betes (A10).
Phase 2: intervention study
In the second phase, 18 pharmacies and 440 patients
were included. The intervention group consisted of 178
of these patients who showed some degree of renal im-
pairment. Four of these patients did not take any drugs
suitable for dosing adjustment in the case of renal im-
pairment and were excluded from the study. Finally, the
Figure 2 Breakdown of percentage Anatomical Groups (ATC).
Table 2 Patient demographic and clinical characteristics
at baseline according to gender (Phase 2)
Mean ± SD Women (103) Men (71) Overall (174)
Age (years) 81. ± 7.5 80.5 ± 7.0 80.8 ± 7.3
Weight (kg) 61.9 ± 10.7 73.9 ± 10.1 66.8 ± 12.0
Height (m) 1.5 ± 0.1 1.7 ± 0.1 1.6 ± 0.1
BMI (Kg/m2) 26.0 ± 4.2 26.6 ± 3.1 26.3 ± 3.8
SBP (mm Hg) 136.3 ± 1932 132.4 ± 17.8 134.7 ± 18.7
DBP (mm Hg) 75.8 ± 12.0 73.9 ± 12.6 75.0 ± 12.6
Creatinine (mg/dl) 1.0 ± 0.3 1.5 ± 1.1 1.2 ± 0.8
Body surface (m2) 1.6 ± 0.2 1.8 ± 0.2 1.7 ± 0.2
GFR (ml/min/1.73 m2) 61.3 ± 14.5 59.8 ± 20.0 60.7 ± 17.0
CrCl (ml/min) 45.2 ± 11.2 46.9 ± 15.2 45.9 ± 12.3
CrCl-BS (ml/min/1.73 m2) 48.3 ± 11.5 45.2 ± 13.9 47.1 ± 12.6
Total number of drugs
per patient
6.3 ± 3.3 6.2 ± 3.0 6.3 ± 3.1
Drugs wit restriction in RI
per patient
3.5 ± 2.1 3.5 ± 2.0 3.5 ± 2.1
Number of DRP per patient 0.4 ± 0.9 0.6 ± 1.0 0.5 ± 0.9
Prevalence of DI (%) 18.9 ± 30.7 12.4 ± 24.2 15.5 ± 28.6
Population with DRP %(n) 35.0(36) 19.7(14) 28.7(50)
Comorbidity %(n)
Hypertension 709.%(73) 67.6%(48) 69.5%(121)
T2Dm 13.6%(14) 8.5%(6) 11.5%(20)
Dyslipidemia 42.%(44) 29.6%(21) 37.4%(65)
Hyper/Hypo/Thy 9.7%(10) 1.4%(1) 6.3%(11)
CVD 19.4%(20) 29.6%(21) 23.6%(41)
Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure, DBP Diastolic
Blood Pressure; T2DM Type 2 Diabetes Mellitus, CVD Cardiovascular Disease,
THY Thyroidism, GFR Rate of Glomerular filtration, CrCl Creatinine Clearance,
CrCl-BS Creatinine Clearance adjusted to body surface, RI renal impairment,
DRP Drug-related problem, DI Dosing inadequacy, Drugs with restrictions
(dose adjustment needed in case of renal impairment (RI)) per patient [20-22],
SD Standard deviation.
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Table 2 describes the general characteristics according
to gender.
These 174 patients were taking a total of 1,092 drug
products of which 614 (56.2% [95% CI 53.3-59.8]) may
have needed dose adjustments or were contra-indicated
according to the patient’s renal functioning.
The mean of the prevalence of dosing inadequacy in
this group was 15.5% [95% CI 14.5-16.6] and the mean
of the DRPs per patient was 0.50 [95% CI 0.4-0.6]
(Table 2).
The distribution of the 614 drugs that show use re-
strictions and/or dosing adjustment in the case of renal
impairment was similar to that in phase one of the
study.
Among the active ingredients which caused DRPs, it
should be mentioned that the C09 sub-group containing
Enalapril and Olmesartan were responsible for 26.4% of
DRPs detected and treated. DRPs detected and treated
with respect to acetyl salicylic acid (group B01) at 8%
and Lormetazepam and Triazolam (group N05) at 9.1%
should also be noted. Metformin and Repaglinide (group
A10) at 3.4%, Ranitidine (group A02) at 4.6%, Simva-
statin (group C10) at 5.7%, Allopurinol (group M04) at
3.4% and Alendronic Acid (group M05) at 2.3% may also
be highlighted.
In the intervention group, pharmacists carried out 167
interventions in 139 patients (1.2 interventions/patient).
In 35 patients (25.8%) no intervention was carried out
because they did not present DRPs or because they were
not considered as suitable for inclusion in a monitoring
programme for patients with renal impairment. Some 34
patients (24.5%) were referred to physicians and they
carried out 38 dose adjustments. Figure 3 shows the type
of recommendations made to GP’s A total of 65.7% of
the interventions had no response from the physicians
while 31.4% of the interventions were accepted and the
DRPs were resolved. Pharmacists included 129 patients
with renal impairment in a monitoring programme for

















Total number of drugs per patient
Drugs with restriction in RI per patient
Number of DRP per patient








Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure, DBP, Diastolic Blood
Kidney Disease, GFR Rate of Glomerular filtration, CrCl Creatinine Clearance, CrCl-BS Cre
problem, DI Dosing inadequacy, Drugs with restrictions (dose adjustment needed in ca
aχ2Test.
b T Student test for independent groups.
Figure 3 Type of recommendations made to GPs in the
intervention group in phase 2.
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1) placing patients under observation before making
dosing adjustments when there was a recommendation
in the databases consulted; 2) observing the prescription
of new drugs that may require dosing adjustments or
surveillance and 3) monitoring of any changes in renal
impairment where dosing adjustment is needed.
In the intervention group, the number of DRPs per
patient fell from 0.5 at the beginning to 0.2 after the phar-
macists’ intervention; showing a difference in the DRPs of
0.3 per patient [95% CI 0.2-0.5] (p < 0.001). Dosing inadequacy
also dropped from 15.5% to 5.2%; a 10.4% difference [95%
CI 6.5-14.3] ( p < 0.001), and the percentage of patients
with DRPs decreased from 28.7% [95% CI 22.0-35.4] atol group and intervention group





83.3 ± 6.9 80.8 ± 7.3 0.001b
65.5 ± 12.1 66.8 ± 12.0 0.335b
1.6 ± 0.1 1.6 ± 0.1 0.069b
26.1 ± 4.0 26.3 ± 3.8 0.721b
130.7 ± 17.3 134.7 ± 18.7 0.060b
71.5 ± 11.3 75.0 ± 12.3 0.012b
1.1 ± 0.4 1.2 ± 0.8 0.052b
1.7 ± 0.2 1.7 ± 0.2 0.162b
61.7 ± 16.5 60.7 ± 17.0 0.572b
45.0 ± 12.1 45. + ±13.0 0.525b
46.3 ± 11.6 47.1 ± 12.6 0.550b
7.3 ± 2.9 6.3 ± 3.2 0.003b
4.0 ± 2.0 3.5 ± 2.1 0.069b
0.7 ± 1.0 0.5 ± 1.0 0.164b







Pressure, T2DM Type 2 Diabetes Mellitus, CVD Cardiovascular Disease, CKD Chronic
atinine Clearace adjusted to body surface, RI renal impairment, DRP Drug-related
se of renal impairment (RI)) per patient [20-22], SD Standard deviation.
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[95% CI 6.8-16.2] (one out of every 10 patients) (p < 0.001).
Finally, we compared the results between the control
and intervention groups. Table 3 shows the homogeneity
between the control group and the intervention group,
allowing comparison between variables that measure the
results of the pharmacist intervention. Some statistically
significant differences were noted; in age (patients in the
control group were 3 years older than patients in the
intervention group), in diastolic blood pressure (it was
higher in the intervention group), in the number of dia-
betics (higher in the control group) and in the number
of total drug products per patient (higher in the control
group). Table 4 shows the results when comparing the
prevalence of dosing inadequacy and DRPs per patient
between the control and intervention groups adjusted by
age, diastolic blood pressure, creatinine, number of total
drugs and comorbidity: T2DM. Statistically significant dif-
ferences were noted (p < 0.001) between the control and
intervention groups in the prevalence of dosing inad-
equacy and in the DRP rate per patient following the phar-
macists’ interventions.
The difference in the prevalence of dosing inadequacy
between the control and intervention group before the
pharmacists’ intervention was 0.73% [95% CI0 (−6.0) -7.5],
and after the pharmacists’ intervention it was 13.5% [95%
CI 8.0-19.5]. The difference in the DRP rate per patient be-
tween the control and intervention group before the phar-
macists’ intervention was 0.05 [95% CI (−0.2) - 0.4] and
following the intervention it was 0.50 [95% CI 0.3 - 0.7].
Discussion
The dosing inadequacy caused by renal impairment has
been described in the bibliography and shows largeTable 4 Comparison between the number of DRPs per patien
control and intervention groups adjusted by age, diastolic bl
comorbidity: T2DM
n
Number of DRPs per patient Pre-INTERVENTION
Control group 176
Intervention group 174
Number of DRPs per patient Post-INTERVENTION
Control group 176
Intervention group 174
Prevalence of DI Pre-Intervention
Control group 176
Intervention group 174
Prevalence of DI Post-Intervention I
Control group 176
Intervention group 174
Abbreviations: DRP Drug-related problem (number per patient), DI Dosing inadequaoscillations (as also shown in the findings of various au-
thors [14,15,23,24]) which indicates the magnitude of
the problem. Our study reveals similar results to other
authors on the subject in distinct types of health care in-
stitutions. Alvarez Arroyo et al. [12] in a hospital-based
study with 185 patients (88 in the control group and 97
in the intervention group), found a frequency of dosing
inadequacy of 22.5% in the control group and 18.7% in
the intervention group. After the pharmaceutical inter-
vention, the frequency of dosing inadequacy went down
by 2.1% and this resulted in lower drug expenditure. An-
other study [13], this one in a geriatric nursing home,
demonstrated dosing inadequacy of 11% in elderly pa-
tients with creatinine clearance below 60 ml/min. After
the pharmaceutical intervention, the inadequacy per-
centage decreased. In this case most of the interventions
were accepted by the physicians due to the collaboration
between both groups of professionals. In another study
on the impact of adjustments in hospitalised patients
with CKD [14], with a very similar design to this one,
the prevalence of inadequacy was about 53%. After the
pharmacists’ interventions this dropped to 27.5%. Sev-
eral patients showed CKD at stage 5, which explains the
great need for dosing adequacy in this case.
A controversial point could be the implication of using
MDRD-4 formula versus Crockroft-Gault formula for
renal dosing adjustments. Several authors [25-30] have
studied the dosing implications of using these two for-
mulae for medication therapy adjustments where differ-
ences were noted according to the formula used. We,
therefore, used both formulae in this study in a simple
and practical way (using the online calculator [19]), and
from the value of Serum Creatinine we calculated the
CrCl and GFR for both formulations. The therapeutict and the prevalence of dosing inadequacy between
ood pressure, creatinine, number of total drugs and









cy (%), CI Confidence Interval, n Number of patients, Ref Group of reference.
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(CIMA [20], Martindale [21], AHFS [22]) which were
consulted for this study. No significant differences were
noted between the separate databases.
One of the limitations of this study was the low re-
sponse from the physicians to the pharmacists’ recom-
mendations; only one out of three recommendations was
followed. But in the cases where the physicians responded
almost all the pharmacists’ suggested interventions were
accepted. One explanation might be that Spanish pharma-
cies are not fully integrated into the public health system
and physicians tend to see the pharmacist as a profes-
sional outside the system. Rubio-Valera et al. [31] examined
the most important factors affecting GP and pharmacist
collaboration. Those related to economic issues, manage-
ment and practitioners’ attitudes and perceptions were
shown to influence this collaboration. The effectiveness of
the pharmacists suggested interventions in dealing with the
issue of dosing inadequacy could have been greater with
better collaboration between health professionals. This con-
clusion is supported by other studies [13-15,32].
This underlines shows a real need for physician/pharma-
cist collaboration, mainly in community healthcare outside
hospitals [33]. Collaboration resolved, as seen in this study,
many DRPs as well as reducing dosing inadequacy.
The study design with historical control group does not
allow us to gather as much scientific evidence as a ran-
domised clinical trial. Despite this, similar designs have
been used in other studies [12-14]. To improve outcome
reliability, the unanswered physicians’ questionnaires were
taken as negative responses to the pharmacists’ recommen-
dations, the DRP was considered unresolved and was then
included in the results pool.
This study emphasizes the need to carry out more accur-
ate monitoring of pharmacological treatment in patients
over 65 with renal impairment, and the requirement to
check renal functioning in the elderly attending commu-
nity pharmacies.
Conclusions
The prevalence of dosing inadequacy in polymedicated pa-
tients over 65 years with renal impairment attending com-
munity pharmacies is not insignificant. The study shows
the effectiveness of a community pharmacist intervention
in addressing the problem of dosing adequacy of drug treat-
ment in polymedicated elderly patients over 65 years with
renal impairment. A drug dosing service for elderly patients
with renal impairment in community pharmacies can de-
tect and solve DRPs. Collaborative practice with physicians
can improve these results.
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